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INTRODUCTION 
In a large patient population, a medication that is proven efficacious in many 
patients often fails to work in some other patients. Furthermore, when it does work, it 
may cause serious side effects, even death, in a small number of patients. Although 
large individual variability in drug efficacy and safety has been known to exist since 
the beginning of human medicine, understanding the origin of individual variation in 
drug response has proven difficult. On the other hand, the demand to overcome such 
variation has received more attention now than ever before. It is well documented that 
large variability of drug efficacy and adverse drug reactions in patients is a major 
determinant of the clinical use, regulation, and withdrawal-from-market of clinical 
drugs and a bottleneck in the development of new therapeutic agents. 
Genetic variation in humans was recognized as an important determinant of 
individual variability of drug response from clinical observations in late 1950s.
[1]
 The 
observation that individual variation of a drug response is often larger among members 
in a population (population variability) than within the same person at different times 
(intrapatient variability) further supports inheritance as a major determinant of drug 
response.
[2]
 These clinical and population-based findings fostered the formation of 
pharmacogenetics to specifically address genetic contribution to individual variability 
in drug therapy. 
The human genome sequence provides a special record of human evolution that 
varies among populations and individuals. Sequence variations in drug target proteins, 
drug-metabolizing enzymes, and drug transporters can alter drug efficacy, drug side 
effects, or both to cause variable drug responses in individual.
 [3]
 From this prospect, 
the availability of the complete human genome sequence has made it possible to 
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analyze the impact of variations of the human genome sequence on the pathogenesis of 
important diseases and the response to drug therapy at an accelerating rate in recent 
years. 
Rheumatoid arthritis has a prevalence of nearly 1% in Indian population
 [46].
 
This autoimmune disease is characterised by chronic inflammatory process within the 
synovial joints, progressive (radiological) joint damage and significant functional 
impairment. 
[45]
 In the last decade patients have been treated with traditional disease 
modifying anti-rheumatic drugs (DMARDs) including methotrexate, sulphasalazine 
and leflunomide, or a combination of DMARDs. Most recently growing evidence for 
the central role of tumour-necrosis factor alpha (TNFα) in the pathogenesis of RA led 
to the introduction of TNFα inhibitors, such as etanercept, infliximab and adalimumab. 
These biological DMARDs has proven to play an important role in the treatment of 
persistant RA in patients, who achieve an incomplete response or develop adverse drug 
events to traditional DMARDs. In addition, biological with alternate mechanisms of 
actions such as rituximab, abatacept and tocilizumab have recently been developed. To 
date, the place of these agents in RA therapy is less established. 
Ideally, RA therapy is based on strict monitoring of disease activity and tight 
control treatment in order to prevent progression of joint damage and functional 
disability. Namely, it is established that high and variable disease activity is related to 
increasing joint damage and that effective intervention stops the progression. In current 
clinical practice, newly diagnosed RA patients are treated with traditional DMARDs, in 
which MTX is the drug of first choice. In case of unfavourable response, side effects 
and/or drug toxicity, alteration of dose regimen or drug therapy towards a combination 
of DMARDs and/or biological is recommended. 
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Still, different response rates are seen in RA patients treated with MTX. 
Substantial percentages of 30-40% of RA patients fail to achieve a satisfactory 
response. Moreover, 15-30% of patients develop adverse drug events. These different 
responses lead to studies identifying influence of demographic, clinical and 
immunological variables on treatment outcome with MTX. Next to these factors, 
genetic influences have also been explored in the last decade. Generally, 
pharmacogenetics has the potential to increase the drug efficacy and to ameliorate 
adverse events. Therefore the application might be of great clinical benefit for 
individuals affected with RA. Studies have reported associations between SNPs in 
genes encoding enzymes related to the pharmacokinetics and pharmacodynamics of 
MTX and treatment outcome. The ultimate aim of using pharmacogenetic markers is to 
predict the probability of a wanted or unwanted drug response in individual patients. 
 MTX is a structural analogue of folic acid which inhibits dihydofolate 
reductase, an enzyme responsible for tetrahydrofolate regeneration. MTX may 
influence several other steps in folate metabolism and cause cellular folate depletion 
and possibly inhibition of methylenetetrahydrofolate reductase (MTHFR). MTHFR 
synthesises 5-methyltetrahydrofolate, which acts as the methyl donor for remethylation 
of homocysteine to methionine. 
Several polymorphisms of the MTHFR gene have been described. The most 
studied C677T polymorphism results in the decreased enzyme activity and 
hyperhomocysteinaemia in the general population. The recently described A1298C 
polymorphism is associated with MTHFR activity and may affect plasma homocysteine 
level. 
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Our aim in the present study were, first to investigate the distribution of 
MTHFR A1298C gene polymorphism in MTX treated RA patients compared with a 
healthy control group; second, to determine the relation between A1298C 
polymorphism and rheumatoid arthritis activity, methotrexate efficacy, and adverse 
effects. 
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AIM AND OBJECTIVES 
 
 The aim of the study is to investigate the single nucleotide polymorphism within 
Methotrexate pathway gene (MTHFR A1298C) related to efficacy and toxicity in Indian 
Rheumatoid arthritis patients  
 
Primary Objective:  
 Genotyping assay to study the distribution of different alleles within the study 
population 
 
Secondary Objectives: 
 To assess the efficacy of MTX therapy by DAS and HAQ. 
 To evaluate the toxicity of MTX. 
 To study the distribution of responders and non-responders to MTX therapy. 
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REVIEW OF LITERATURE 
Rheumatoid arthritis is a common highly inflammatory, destructive poly 
arthropathy. It affects approximately 0.75% to 1% of the population. 80% of affected 
patients are disabled after 20 years and life expectancy is reduced by an average of 3 to 
18 years. Women are three times more likely than men to develop rheumatoid arthritis. 
Women typically experience a more severe and delimiting form of disease. Most 
patients diagnosed are between the ages of 35 and 60. 
The process involves an inflammatory response of the capsule around the joints 
(synovium) secondary to swelling (turgescence) of synovial cells, excess synovial fluid, 
and the development of fibrous tissue (pannus) in the synovium. The pathology of the 
disease process often leads to the destruction of articular cartilage 
and ankylosis (fusion) of the joints. RA can also produce diffuse inflammation in 
the lungs, the membrane around the heart (pericardium), the membranes of the lung 
(pleura), and white of the eye (sclera), and also nodular lesions, most common 
in subcutaneous tissue. Although the cause of RA is unknown, autoimmunity plays a 
big part, and RA is a systemic autoimmune disease. It is a clinical diagnosis made on 
the basis of symptoms, physical exam, radiographs (X-rays) and labs.
[1]
 
Treatments are pharmacological and non-pharmacological. Non-
pharmacological treatment includes physical therapy, occupational therapy and 
nutritional therapy but these do not stop the progression of joint destruction. Analgesics 
and anti-inflammatory drugs, including steroids, suppress symptoms, but do not stop 
the progression of joint destruction either. Disease-modifying anti-rheumatic 
drugs (DMARDs) slow or halt the progress of the disease.  
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Methotrexate is the cornerstone for the therapy of rheumatoid arthritis in spite 
of the advent of newer biologics. MTX is fast acting and has best efficacy: toxicity 
ratio and also cheaper. For the treatment of RA it was first introduced in 1951, but after 
30years only widespread use in RA came into force in 1985. It is used at the dose of 5-
25mg/week in treatment of RA and the dose for its anticancer effect is 5000mg/week. 
As a gold standard it is started as monotherapy, low dose is safe and well tolerated. For 
patients unresponsive to NSAIDs it is still the first-line drug for therapy in RA 
[1]
.  
MTX is taken up by the cells glutamated by Foly-poly glutamyl synthase 
(FPGS) and there is a competition by Gamma glutamyl hydrolase (GGH), which 
deconjugates the drug and the free drug is effluxed by ATP-binding cassette (ABC) 
proteins. Polyglutamation upto 7 subunits takes place and methotrexate-polyglutamates 
(MTX-PG5-7) roughly correlates with the therapeutic efficacy of the drug. Free MTX is 
eliminated within 24hrs and a small portion of it is metabolized in liver to 7-
hydroxymethotrexate.  
At cellular level MTX and MTX-PGs inhibit several enzymes of purine, 
pyrimidine biosynthesis and also exert anti-inflammatory effect. The key enzymes 
inhibited are dihydrofolate reductase (DHFR), which causes reduction of dihydrofolate 
to tetrahydrofolate, essential in synthesis of precursors of DNA; thymidylate synthase 
(TYMS), a key enzyme involved in pyrimidine synthesis, essential for cellular 
proliferation and AICAR transformylase is most potently inhibited, which leads to 
accumulation of 5-aminoimidazole- 4-carboxamide ribonucleotide (AICAR), inhibition 
of several key enzymes involved such as adenosine monophosphate deaminase 
(AMPD1) and collectively this leads to accumulation of adenosine, which has anti-
inflammatory effect. The other enzymes inhibited by the drug are homocysteine 
pathway enzymes such as methylenetetrahydrofolate reductase (MTHFR), methionine 
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synthase reductase (MTRR) and methionine synthase (MS), which could lead to 
accumulation of homocysteine and related adverse effects 
[2]
. 
Because of variation in response and toxicity profile 1/3
rd
 of the patients 
discontinue therapy due to its adverse effects. Folate antagonism leads to anemia, 
stomatitis, oral ulcers and elevation of transaminases in liver, which could be alleviated 
by administration of folic or folinic acid. Accumulation of adenosine also leads to GI 
AEs. The uncommon toxicities are nodulosis, hepatic fibrosis, pulmonary fibrosis, and 
renal insufficiency 
[3]
.  
Because of these factors, it is essential to predict the efficacy and adverse 
effects before administration, to effectively use the drug in treatment of RA. Since the 
drug is excreted within 24hrs and measurement of MTX-PGs routinely in clinical 
practice is not feasible, pharmacogenetics could be a useful tool to monitor the 
treatment outcomes. 
PHARMACOGENETICS OF METHOTREXATE  
GENES RELATED TO INFLUX AND EFFLUX  
ABCB1 C3435T 
This is one of the important genes related to P-gp expression, which are best 
drug transporters in humans. There are several genes and several polymorphisms 
related to multiple drug resistance and ABCB1 C3435T is widely studied in RA 
patients and this gene is otherwise called as MDR1 gene.   
The distribution of this polymorphism in RA was similar to healthy individuals 
in a Polish study by Pawlik et al 
[4]
, but different from Afro-Americans, Chinese, and 
Japanese healthy individuals 
[5]
. The same group studied this polymorphism in 255 
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Polish RA patients and reported that carriers of TT genotype were found to be 
responders 
[6]
.  
Conversely Takatori et al reported that the efflux of MTX was increased in TT 
genotype and due to this they are non-responders and insisted for increasing the dose 
during early stages of RA or substitution with biologics (17181924). 
Kato et al studied the effect of C3435T polymorphism in Japanese RA patients 
and found that the remission defined by lower DAS score is higher in TT genotype 
[7]
. 
In a study by Sharma et al, CT genotypes were found to be non-responders 
[8]
.  
RFC-1 G80A  
Reduced folate carrier (RFC) is a anion exchanger, transmembrane protein 
comprising 591 aminoacids and transfers folates across the cell membrane. This 
polymorphism is otherwise called as solute carrier, SLC19A1 G80A.  
Reduced folate carrier influences the entry of methotrexate into the cells and the 
carriers of AA alleles had increased MTX levels than GG or AG alleles, by increased 
up take in B and CD4+ cells. This study suggests that this polymorphism is relevant for 
deciding the dosage of MTX in autoimmune disorders 
[9]
.  
Drozdzik et al reported that the remission in RA patients is increased, when 
they have the 80AA genotype and the frequency of A allele was higher in the 
responders group, in a study of 174 RA patients. They also reported increase in 
transaminase levels in this genotype 
[10]
. 
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Hayashi et al reported that the AA allele genotypes had increased intracellular 
MTX up take, increased efficacy and the need for combination with biologics is less, 
and this polymorphism influences MTX efficacy in Japanese RA patients 
[11]
. 
Dervieux et al studied the effects of this polymorphism in 226 RA patients and 
reported that carriers of AA genotype have higher MTX-PG levels and thus influences 
polyglutamation 
[12]
.  
GENES RELATED TO POLYGLUTAMATION  
GGH  
Gamma glutamyl hydrolase is a lysosomal peptidase that catalyzes elimination 
of gamma linked polyglutamates. Long chain MTX-PGs are converted to short chain 
MTX-PGs and further converted back to MTX and effluxed from the cell. Since the 
MTX-PGs are associated with disease activity in rheumatoid arthritis, GGH 
polymorphisms could influence the therapeutic outcome. Three polymorphisms had 
been reported in previous studies such as GGH C401T, GGH C452T, & GGH T16C.  
Dervieux et al C401T in 226 RA patients and found that the carriers of TT 
genotype had lesser MTX-PG levels when compared to the wild-type and the 
heterozygous mutants, and thus this polymorphism influences polyglutamation 
[12]
. 
Chave et al studied expression of the polymorphisms in this gene which affects 
its functional activity in MCF-7 cells and reported that C401T & T124G 
polymorphisms enhanced hGGH protein expression, which could increase resistance to 
MTX 
[13]
. 
Hayashi et al reported that in Japanese healthy population, the frequency of 
C452T polymorphism in 269 healthy Japanese individuals and found that the 
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distribution of this polymorphism is similar to Afro-Americans and slightly different 
with Caucasians 
[14]
. 
In juvenile idiopathic arthritis, Yanagimachi et al studied the effect of T16C 
polymorphism in 92 Japanese patients and reported that TT genotype was associated 
with higher incidence of liver dysfunction 
[15]
. 
FPGS 
This gene is related to polyglutamation of MTX and is important in one-carbon 
metabolism. 
In a study by Oppeneer et al they found this gene is not associated with 
homocysteine metabolism 
[16]
.  
Sharma et al reported that a polymorphism in this gene (rs1544105) is 
associated with poor response to MTX therapy in RA 
[17]
. 
In UK rheumatoid cohort study by Owen et al, they found that FPGS 
polymorphism was associated with adverse effects 
[18]
. 
GENES RELATED TO HOMOCYSTEINE PATHWAY 
MTHFR  
This gene encodes an enzyme that catalyzes reduction of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, a carbon donor in the 
metabolism of folate  to methionine and the polymorphism leads to reduction in 
enzyme activity and associated with hyperhomocystinemia.  
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There were about dozen polymorphisms in this gene and in meta-analysis study 
of pharmacogenetics of methotrexate by Fischer et al, it was identified that MTHFR 
C677T & A1298C were the widely studied gene polymorphisms 
[19]
.  
This polymorphism C677T was first reported by Frosst et al in 1995 
[20]
 and the 
second polymorphism A1298C was reported by Weisberg et al in 1998 
[21]
. In C677T 
heterozygous mutants have ~40% reduction in enzyme activity and homozygous 
mutants have ~70% reduction and this leads to thermolabile variant of the enzyme. In 
A1298C polymorphism the homozygous mutants have about ~40% reduction in 
enzyme activity  
The first article related to this polymorphism C677T was published by van Ede 
et al which assessed discontinuation of MTX due to elevation of transaminases. In this 
study it was concluded that the elevation of liver enzymes is due to homocysteine 
metabolism and supplementation with folic acid or folinic acid reduced the toxicity-
related discontinuation rates 
[22]
. 
Urano et al in 2002 assessed both C677T & A1298C polymorphisms in this 
gene and found A1298C polymorphism rendered the patients sensitive to MTX 
treatment, whereas C677T rendered the patients prone for toxicity 
[23]
. In haplotype 
analysis 677C-1298C were receiving lower dose of MTX and 677T-1298A had a 
higher frequency of side-effects from MTX. The reported toxicities were elevation of 
transaminases, gastrointestinal (GI) disturbances, hair loss, fatigue and rash. The same 
was confirmed in their second study published in the year 2007
[24]
. In their next study 
in 2009, the same group also reported that these two polymorphisms are not associated 
with fracture 
[25]
.  
                                                                           Review of Literature 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 13 
 
Haagsma et al reported a persistent increase in homocysteine levels in TT 
alleles of MTHFR C677T and is associated with GI adverse events (AEs) 
[26]
 and 
elevation of liver enzymes 
[22]
. Concomitant administration of folic acid prevents these 
adverse effects 
[27]
.  
Hider et al demonstrated that T allele is associated with elevation of liver 
enzymes in 309 RA patients 
[28]
.  
Berkun et al reported that the allele frequency of 1298CC was higher in RA 
population and the carriers of 1298AA allele had higher frequency of adverse effects in 
spite of higher folic acid supplementation and 1298CC may protect against MTX 
related adverse effects, conducted in 93 RA patients in Israel 
[29]
.  
Hughes et al studied the allelic frequencies of MTHFR C677T, A1298C & 
rs4846051 in Caucasians and Afro-Americans and highlighted racial or ethnic 
differences in it. 1298 A allele was associated with MTX-related adverse events in 
Caucasians, whereas the rs4846051 C allele appears to be related to MTX toxicity in 
African-Americans, so different alleles in different race may be the markers for 
response and toxicity 
[30]
.  
Wessels et al reported MTHFR 1298AA was associated with less improvement 
relative to mutants and MTHFR 1298C allele carriers developed more adverse effects 
[31]
.  
Aggarwal et al studied the effect of C677T polymorphism in north Indians, 150 
patients were recruited in the study. All the patients received folic acid supplementation 
and they concluded that this polymorphism is not predictive of efficacy or toxicity 
[32]
.  
                                                                           Review of Literature 
 
INSTITUTE OF PHARMACOLOGY, MMC Page 14 
 
Kim et al studied C677T polymorphism in 385 Korean RA patients, and found 
the frequency of TT genotypes were higher, the cost of therapy decreased with the 
probability of continuation with MTX also increased 
[33]
.  
Kato et al studied the effect of MTHFR A1298C and reported that AA 
genotypes were associated with good response [
7]
. 
Brambilla-Tapia et al studied this MTHFR C677T in 71 RA patients and 
carriers of T alleles (TT homozygotes), had lower BMD and reported to have increased 
risk of osteoporosis and folic acid supplementation is suggested as a prophylactic 
measure 
[34]
.  
Graber et al reported that MTHFR A1298C polymorphism is protective related 
to adverse effects of MTX 
[35]
.  
In a recent study by Davis et al, they found that A1298C polymorphism was 
associated with adverse effects and increased copies of this leads to higher incidence of 
AEs 
[36]
.  
GENES RELATED TO PYRIMIDINE PATHWAY  
TYMS or TSER *2/*3 
Dervieux et al assessed this polymorphism and concluded that patients having 
two tandem repeats had better clinical response than triple repeat 
[2]
.  
Kumagai et al assessed the impact of this polymorphism in Japanese RA 
patients, and found that triple-repeat allele of the polymorphism (*3/*3) received 
higher dose of MTX than double repeat allele 
[37]
.  
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TYMS or TSER 3’UTR 6bp deletion TTAAAG 
Kumagai et al studied this polymorphism in Japanese RA patients and has 
shown that this 6bp deletion leads to decrease in CRP levels and improvement in 
response 
[37]
.  
This deletion polymorphism is associated with decreased expression of mRNA 
and could increase the drug response in RA patients 
[38]
.  
TYMS (rs2853539) 
Sharma et al studied the effect of this polymorphism in RA patients and found 
that carriers of AA genotype are non-responders 
[17]
.  
GENES RELATED TO ADENOSINE PATHWAY  
Blockade of AICAR affects purine synthesis and leads to accumulation of 
adenosine and the anti-inflammatory effects of MTX are mediated through this 
pathway. The polymorphisms in genes influencing anti-inflammatory adenosine release 
are 5-aminoimidazole- 4-carboxamide ribonucleotide transformylase (ATIC) C347G, 
inosine triphosphate pyrophosphatase (ITPA) C94A, AMPD1 C34T & adenosine 
receptors (ADORA) 2a. Methotrexate inhibits the deamination of adenosine and 
modulates its pharmacokinetics and pharmacodynamics. Adenosine exhibits its anti-
inflammatory effect through modulation of inflammatory cells.  
Adenosine binds to several receptors such as A1, A2a, A2b, A. ADORA 2a is 
highly expressed in synovium of RA patients receiving MTX and SNPs in this gene is 
reported to influence adverse effect profile of MTX 
[39]
.  
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Hider et al studied five SNPs in ADORA 2a in 309 RA patients (rs 5760410, rs 
2298383, rs 3761422, rs 2267076 & rs 2236624) and found an association with GI 
AEs. The possible explanations were anti-proliferative effects in the gut and 
sensitization of chemoreceptors in brain due to this polymorphism and could be 
alleviated by administration of folic acid and 5HT3 antagonists 
[40]
.  
Wessels et al reported favorable alleles for response as T allele of AMPD1, CC 
allele of ATIC C347G & CC allele of ITPA C94A. Regarding toxicity, G allele of 
ATIC C347G was associated with GI AEs 
[41]
. 
ATIC rs4673993 was assessed and reported as associated with low disease 
activity in a study 
[42]
. 
GENES RELATED TO FOLATE METABOLISM  
DHFR 
This is a key enzyme inhibited by MTX and polymorphisms in it are less 
studied. It has reported polymorphisms such as rs12517451, rs10072026, and 
rs1643657, associated with adverse effects 
[18]
. 
DHFR A317G was studied by Milic et al and found that 317AA genotypes were 
associated with poor response 
[43]
.  
POLYGENETIC ANALYSIS  
Dervieux et al studied the combined effect of RFC G80A, ATIC C347G and 
TSER 2*/3* polymorphisms in 108 RA patients in relation with MTX-PG and efficacy. 
Favorable alleles were reported to be homozygotes of these polymorphisms (RFC-1 
AA, ATIC 347GG, TSER *2/*2) and a Pharmacogenetic index was calculated. Patients 
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having all the favorable alleles were reported to have increased RBC-MTX PG levels 
and improvement in disease activity (reduction in pain, tender joint count, swollen joint 
count & physician’s global assessment) compared to non-carriers of all the genotypes. 
The outcome of the study reports Pharmacogenetic and metabolite measurements are 
useful in optimizing MTX treatment 
[2]
.  
In a study with 48 RA patients, the effect of GGH C401T, ATIC C347T, 
MTHFR A1298C, MTRR A2756G & MS A66G combinations were studied by 
Dervieux et al. The risk alleles were identified as GGH 401CC, ATIC 347GG, MTHFR 
1298 AC/CC, MTRR 2756AA & MS 66GG. These genotypes were found to be 
associated with CNS and gastrointestinal adverse effects 
[44]
.   
Wessels et al studied the polygenetic effect of genes related to adenosine 
release and reported that the carriers of T allele of AMPD1, CC allele of ATIC C347G 
& CC allele of ITPA C94A are good responders 
[41]
 
Weisman et al studied the polygenic effects of MTHFR C677T, TYMS *2/*3, 
ATIC C34TG & serine hydroxyl methyl transferase (SHMT) C1420T and found the 
risk genotypes were TT alleles of MTHFR C677T (CNS AE), CC alleles of SHMT 
C1420T (CNS AE & alopecia),  
GG alleles of ATIC C34TG (GI AE) and *2/*2 alleles of TYMS *2/*3 
(alopecia) 
[45]
 (16447238).  
The allelic frequencies were recorded from different studies and represented in 
Table 2. This table depicts racial and ethnic differences 
[46, 47]
. 
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MATERIALS USED 
List of chemicals used for the DNA isolation, PCR and RFLP 
Chemicals Manufacturer 
10x PCR buffer Invitrogen 
50bp ladder DNA Fermentas 
50mm MgCl2 Invitrogen 
Agarose Lonza 
Ammonium acetate Merc 
Ammonium chloride Srl 
Boric acid Srl 
Chloroform Srl 
dNTPs Biolabs 
EDTA Srl 
Ethanol Hayman specality products 
Ethidium bromide Genei 
Hydrochloric acid Srl 
Isoamyl alcohol Srl 
Mbo II enzyme Thermo scientific 
Milli Q water Sigma 
MTHFR FP Sigma 
MTHFR RP Sigma 
Phenol Srl 
Potassium bicarbonate Loba chemie 
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Premix loading dye Thermo scientific 
Proteinase k Invitrogen 
SDS Srl 
Sodium chloride Srl 
Sodium hydroxide Srl 
Taq DNA polymerase Invitrogen 
Tris Srl 
 
Lab-wares and Instruments 
Lab-wares / Instruments Manufacturer 
Sterile K3EDTA Vacutainer BD 
96 Wellplate Pipettman 
Centrifuge Tubes Torsons 
Effendorf Tubes Torsons 
Micro pipets Thermo Scientific 
Seal mat Pipettman 
Single use Syringe 2ml Dispovan 
Centifuge Remi equipments 
Electrophoresis chamber BroViga 
GelDoc Imager BioRad 
Incubator Remi equipments 
Magnetic Stirrer SPINIT 
Microwave oven LG 
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Mini centrifuge cubee 
NanoDrop Remi equipments 
PCR (Mod.no.2720) Applied biosciences 
pH meter Remi equipments 
Refrigirator LG 
Roto mixer Remi equipments 
Vortex micxer (Model No CM101) Remi equipments 
Water bath Amersham 
Weighing balance (CX 220) Citizen 
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    METHODOLOGY 
STUDY DESIGN 
 Pharmacogenetic study 
STUDY TYPE 
 Prospective, non- interventional study 
STUDY CENTER 
 Department of rheumatology, Rajiv Gandhi Government General Hospital,  
Chennai-03. 
 Institute of pharmacology, Madras Medical College, Chennai-03. 
 Department of Molecular Genetics, MDRF Siruseri, Chennai-103. 
STUDY PERIOD 
 Feb 2013 to Feb 2014. 
STUDY POPULATION 
 Rheumatoid arthritis patients on MTX therapy attending Rheumatology 
department, Rajiv Gandhi Government General Hospital, Chennai. 
SAMPLE SIZE  
 100 patients with RA and 50 age matched healthy volunteers. (Faculty 
members, Staffs and Students from Madras Medical College, Chennai those who met 
the age group served as control group) 
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 SUBJECT SELECTION 
Inclusion Criteria: 
 Age : ≥ 18 years 
 Sex : Both genders 
 Patients willing to give written informed consent 
 Recently diagnosed Rheumatoid arthritis patients receiving MTX therapy 
and/or patients on MTX therapy for less than 2 years 
Exclusion Criteria 
 Patients with liver function abnormalities, GI disturbances, Cardiac and Renal 
diseases. 
STUDY PROCEDURE 
Ethical consideration 
 The protocol was prepared and submitted to the Institutional Ethics 
Committee, Madras Medical College, Chennai and approval was obtained. (IEC 
approval NO.18032013) 
Selection of patients 
 Patients who were diagnosed with history of RA and admitted in the ward of 
Rheumatology department were explained about the study procedure and purpose and 
those who were willing to participate were enrolled.    
 Those who met inclusion criteria were recruited and informed consent was 
obtained prior to any study related procedure. 
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Clinical investigations 
 Detailed medical history, Clinical examination and baseline laboratory 
investigations were documented. The following reports were documented from their 
medical records during baseline visit and also during subsequent visits. 
Disease characteristics 
Morning stiffness  
Pain scale 
TJC, SJC, HAQ and DAS 
 
Drug characteristics 
Dose of MTX 
 
Biochemical characteristics  
SGOT, SGPT and ESR 
 
Adverse effects  
 Adverse effects were noted and recorded. 
 
 Those who fulfilled the inclusion and exclusion criteria were enrolled and the 
demographic details and vitals were recorder. Then 2ml of blood was drawn for genetic 
analysis. 
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Blood sample collection 
 2ml of blood Sample was drawn by disposable syringe and transferred into BD 
vacutainer tubes containing EDTA. They were stored at 4ﹾC until transportation to 
Department of Molecular Genetics, MDRF, Siruseri, Chennai. The blood samples were 
stored at 4ﹾC until processing. 
DETERMINATION OF GENOTYPE OF THE PATIENTS 
The genotyping of blood samples involved the following steps 
1. Extraction of DNA from whole blood. 
2. Quality checking and quantification by using spectrophotometer. 
3. Polymerase Chain Reaction (PCR) for MTHFR gene. 
4. Identification of genotype with Restriction Fragment Length Polymorphism 
(RFLP) using Agarose gel electrophoresis. 
DNA isolation and purification: 
 The phenol chloroform method of DNA isolation was used in this study. This 
frequently used method for DNA isolation removes proteins and other cellular 
components from nucleic acids, resulting in relatively pure DNA preparations. 
Principle: 
 The concept of isolation of DNA is that, all the other components of the cell 
and chromatin are removed using suitable methods to leave behind the DNA. In general 
the isolation of DNA from mammalian tissues follows four different steps. 
1. Lysis of cells with a detergent like sodium dodecyl sulphate (SDS). 
2. Digestion of proteins with enzyme (Proteinase-K). 
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3. Extraction of DNA by phenol chloroform method. 
4. Precipitation of DNA with isopropyl alcohol or 100% ethanol. 
Reagents and their functions: 
a) 10 x Lysis buffer 
0.77M Ammonium chloride - 41.18 g 
0.046M KHCO3  - 4.6 g 
Make up to 1000 ml with distilled water. For the DNA extraction, pH 
 
b) 2X Lysis Mix 
  200ml of 10X Lysis made up to 1000ml with Milli-Q water. 
 
c) 500mM EDTA 
 EDTA   -186.1g 
 Distilled water  -1000ml 
  186.1g of EDTA with 800ml water (Use magnetic stirrer). Dissolve it 
using NaOH pellets and Con.HCl to bring the pH 7.5 and then volume adjusted to 
1000ml with water. 
 
d) SALT / EDTA Buffer 
 0.075M NaCl   - 4.39g 
 0.025M EDTA  - 50ml of 500mM EDTA 
 Distilled water  - up to 1000ml 
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e) 10% SDS solution 
  10g of SDS is dissolved in 100ml distilled water 
 
f) Proteinase K 
  20mg in 1ml distilled water. 
 
g) Ammonium Acetate 
  96.35g of Ammonium Acetate dissolved in 250ml of deionised water. 
 
h) 1M Tris 
 121.4gm of Tris is dissolved in 700ml Milli-Q water. Adjust the pH to 8 
by using NaOH or Con HCl and then volume made up to 1000ml with water. 
 
Roles of chemicals in DNA isolation 
NH4Cl 
  For the DNA extraction, pH should be in 7-8 range, so these compounds are 
used to maintain the pH of the solution. They act as a buffer in Lysis. 
NaCl, KHCO3 
 Salt would attract the phosphate ends of DNA; it pulls away the DNA from 
other substances present in the sample and protects the DNA from surroundings. 
SDS  
 A detergent used to lyse the cells. 
 
                                                                      Materials and Methods 
 
INSTITUTE OF PHARMACOLOGY, MMC  Page 31 
 
Proteinase K   
 This protease enzyme used to digest the cell surface proteins. When cell 
surface proteins are digested, the integrity of the cell membrane is compromised 
leading to cell Lysis. 
EDTA 
 Chelates divalent cations required for DNAse activity, protecting the DNA 
from degradation. 
Phenol and Chloroform 
  Extract proteins and lipids away from the DNA. 
 
Cold alcohol and Ammonium acetate 
 Chilled absolute ethanol precipitates the DNA, the last step in a traditional 
DNA extraction. Ammonium acetate aids the DNA extraction. 
 
Tris   
 Buffer used to maintain the pH. Additionally, it plays an important role in cell 
Lysis. 
 
PROCEDURE OF GENOMIC DNA ISOLATION  
1. The blood samples were carefully transferred to a new graduated centrifuge 
tube and 2x Lysis buffer was added to the sample. ( three times of the volume of 
blood) 
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2. These tubes were mixed in rotator at 25 rpm for 10 minutes and kept in the 
refrigerator for 25 minutes. 
3. The samples were centrifuged at 2000 rpm for 25 minutes and the supernatant 
was discarded, the pellet then treated with 1 ml salt EDTA, 0.1 ml SDS and 
0.01ml proteinase k. then vortexed, mixed well and incubated at 37 C for 12 
hours. 
4. The incubated samples then added twice the volume of phenol and mixed by 
rotator for 10 minutes and spun at 2000 rpm for 10 minutes. 
5. The supernatant again subjected to the previous step. 
6. From the above mixture the supernatant were collected and transferred to a new 
tube and 2ml of chloroform: Isoamyl alcohol (24:1) was added and mixed by 
rotator and spun at 2000 rpm for 10 minutes. 
7. The supernatant again subjected to the previous step. 
8. The upper aqueous phase alone carefully collected with the help of wide bore 
tips without disturbing the other layers and transferred to a new tube. 
9. To this aqueous phase, 0.75 ml of ammonium acetate and twice the volume of 
chilled absolute ethanol were added and tubes were inverted gently for several 
times. 
10. The DNA will be visible like a thread and will assume the shape of a cotton 
ball. 
11. The DNA was transferred to an eppendorf tube and was air-dried in a sterile 
place for 3 hours to remove any trace of residual ethanol. 
12. Appropriate amount of 1X TBE was added according to the amount of the 
DNA, allowed to dissolve and stored at 4ﹾC. 
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QUALITY CHECK AND QUANTIFICATION OF DNA 
 The integrity of the DNA was assessed by running it in 0.7% Agarose gel. 
Further the quantification and quality check of DNA was performed by subjecting the 
DNA to spectrophotometry.  
Principle: 
 The concept of quality check of DNA is to find out the purity of the extracted 
DNA. The extracted DNA may contain impurities like phenol, proteins and others. The 
integrity of the DNA is checked by agarose gel electrophoresis. The intact high 
molecular weight DNA will appear as sharp band without smearing. 
Reagents 
a) TAE buffer (10x) 
Tris base  - 48.4g 
Glacial acetic acid - 11.42ml 
0.5M EDTA (pH 8.0) - 20ml 
  Distilled water was added and made up to 1000ml. autoclaved and 
stored at room temperature. 
 
b) Sodium Borate Buffer (20x) 
Sodium Hydroxide (200mM) - 8g 
Boric Acid (760mM)  - 47g 
  In 800ml of distilled water, the above components added and dissolved. 
pH adjusted to 8.2 using NaOH and made up to 1000ml. sterilized by 
autoclaving and stored at room temperature. 
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c) Gel loading dye- Type III (6x) 
Bomophenol blue -  0.25% (w/v) 
Xylene cyanol FF -  0.25% (w/v) 
Glycerol in water -  30% (v/v) 
  These compounds were mixed well by stirring and stored as 1ml 
aliquots at -20ﹾC. 
 
d) Ethidium bromide (10µg/µl) 
  10mg of Ethidium bromide was added to 1ml of sterile distilled water 
and mixed well to ensure that the dye has dissolved completely. The tube was 
wrapped in aluminium foil and stored at 4ﹾC. 
 
PROCEDURE FOR AGAROSE GEL ELECTROPHORESIS: 
1. 0.7% agarose gel (For Genomic DNA) and 3% agarose gel (for PCR and RFLP 
products) were made using 0.5x TAE buffer (For Genomic DNA) and 1x TAE 
buffer (for PCR/RFLP Products) 5µl of ethidium bromide (10µg/µl) for 100ml 
of agarose gel added and mixed well. After polymerization the gel was placed 
and immersed in the electrophoresis tank with respective buffer. 
2. 1µl of each Genomic DNA sample was taken and mixed with 2µl of 6x loading 
dye and 8µl of sterile double distilled water prior loading. 
3. The PCR products or RFLP products were mixed with 2µl of 6x loading dye 
prior loading. 
4. The samples were loaded into the wells and resolved at 100V-135V for 20min-
35min in Agarose Gel electrophoresis unit. 
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5. 5µl of 50bp DNA ladder loaded for reference while resolving PCR/RFLP 
Products. 
6. After the complete run, gel was documented in UV-Gel Doc system and the 
image was stored as jpeg file. 
 
PROCEDURE FOR UV-SPECTROPHOTOMETRY: 
 The nucleic acid sample was analysed at 260nm and 280nm by using (Nano 
Drop) Spectrophotometer. The concentration and purity of the sample was analysed 
using the following formula, 
 
a) Concentration of DNA: 
         A260 x 50 
Concentration of double stranded DNA sample (µg/µl) = ---------------------- 
              1000 
 
b) Purity of DNA: 
Pure DNA = A260 / A280 ≥ 1.8 
  A260 / A280 < 1.8 indicates protein and phenol contamination. 
  A260 / A280 > 2.0 indicates the possible contamination with RNA. 
 
2. POLYMERASE CHAIN REACTION: 
 The polymerase chain reaction (PCR) is used to amplify a desired region of the 
genome enzymatically without using a living organism.  The concentration of the 
desired target sequence theoretically increases from one molecule to several million 
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copies.  There are three steps to any polymerase chain reaction which are cycled about 
25-35 times, which are: 
a. Denaturation:  This step occurs at 95ﹾC and entails the uncoiling of double 
stranded DNA into 2 single strands by breaking apart the hydrogen bonds. 
 
b. Annealing:  This occurs at 55-65ﹾC.  A pair of short (17-20) oligonucleotide 
sequences called primers anneal to the ends of the template strands of DNA and 
begin the reaction.  The temperature of this stage depends on the primers and is 
usually 5ﹾC below their melting temperature. 
 
 
c. Extension:  This occurs at 72ﹾC and entails the extension of the primers to form 
a new strand that is complimentary to the template strand.  This occurs in the 
presence of the Taq DNA polymerase, a DNA polymerase isolated from the 
organism Thermus aquaticus, a bacterium that can survive high temperature 
without denaturation. 
 
COMPONENT OF PCR: 
The following components are used for the PCR mixture. 
a. 10X PCR buffer 
b. Magnesium chloride 
c. dNTp: dATP + dTTP + dCTP + dGTP 
d. Forward and Reverse primers 
e. Taq DNA polymerase 
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PCR STANDARDIZATION 
The protocol has to be standardized for the following parameters 
a. Annealing temperature:  Using the Ta obtained from the equation [Ta = Tm - 
5ﹾC, where Tm = 2(A+T) + 4(G+C), the protocol is run at Ta±3ﹾ and the Ta with 
best results is chosen. 
 
b. Magnesium chloride concentration:  The dNTPs require MgCl2 to facilitate 
the cleavage of nucleotide from the tri-phosphate group.  At the same time in 
the presence of excess MgCl2, the dNTPs intercalate and are no longer 
available for the PCR. 
 
c. Cycle time and cycle number:  The protocol must also be standardized for the 
number of cycles and the time for each step in the cycle.  The usual cycle times 
tested are that of 30 and 45s respectively.  The number of cycles varies from 25 
– 35. 
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PROCEDURE 
1. Prepare a master mix (cocktail) for the no. of samples required in a 1.5 ml 
Eppendorf tube as follows 
 
Components Volume per reaction 
10X Buffer 2.5µl 
MgCl2 0.75 µl 
dNTPs 0.5 µl 
Taq polymerase 0.1 µl 
Forward primer 1.0 µl 
Reverse primer 1.0 µl 
Distilled water 18.15 µl 
Total 24 µl 
 
2. Add 1µl of DNA template to the tubes on the work bench. 
3. Place tubes in Thermal Cycler and run the cycler for: 
Initial denaturation - 94ﹾC – 5 min 
Denaturation  -94ﹾC – 45 sec 
Annealing  -55ﹾC – 54 sec   30 cycles 
Extension  -72ﹾC – 45 sec 
Final Extension -72ﹾC – 10 min 
  Incubate at   -4ﹾC 
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 Following PCR, positive amplification is checked by running 5µl of the 
amplified product mixed with bromophenol blue-xylene cyanol dye, on an ethidium 
bromide stained 3% agarose gel. 
Primers used in this study 
SNP PRIMERS 
MTHFR 1298 A>C FP: 5’-CAAGGAGGAGCTGCTGAAGA 
RP: 5’ –CCACTCCAGCATCACTCACT 
 
Primer dilution 
 The primer was obtained as lyophilized powder and was reconstituted in 
appropriate volume of sterile distilled water to a concentration of 100µM. A working 
stock of 5pM /µl was prepared and all the stocks of primers stored at -20ﹾC. 
 
RESTRICTION FRAGMENT LENTH POLYMORPHISM (RFLP) 
Principle: 
 In this method, DNA sequence variation is identified by amplification of the 
region using polymerase chain reaction followed by digestion of the amplified product 
with a restriction endonuclease known to be capable of distinguishing the polymorphic 
patterns. The restriction fragments vary in size and can be revealed as different bands 
on gel electrophoresis. 
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Restriction Digestion Composition 
 
 
 
 
 
Procedure 
 Pipette PCR product separately to each labelled tube and prepare master mix of 
the remaining items for the required number of samples. 
 Dispense 5µl of master mix into each tube containing PCR product. 
 Spin the tubes briefly to collect the contents at the bottom and incubate at 37ﹾC 
overnight in a water bath. 
Restriction Digestion based genotype: 
 After the completion of the restriction digestion, the samples were resolved in 
3% agarose gel using Tris borate buffer at 135V for 35 min and the UV-Gel document 
was used to reveal the genotype of each sample based on their restriction pattern as   
Components Volume per reaction 
Mbo II enzyme 0.4µl 
10X buffer 1.5µl 
Distilled water 3.1µl 
Total 5.0µl 
SNP 
annotation and 
ID 
PCR product 
(bp) 
Enzyme for RFLP 
and condition 
Digestion pattern and 
Genotype 
MTHFR 1298 
A>C 
128 Mbo II  at 37ﹾC  
overnight 
28,28 &72bp(AA) 
28 & 100bp (CC) 
28,72&100bp(AC) 
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RESULTS 
A total of 100 RA and 50 age-matched control subjects were enrolled in the study. 
The characteristics of RA and control subjects are presented in Table 1. There was no 
significant difference between mean age and gender among control and RA patients 
(p>0.05). Most of the patients were at the early stages of the disease with duration of ~ 
2yrs. The mean duration of MTX treatment was less than 2yrs and the mean dose were 
found to be less than 10mg/week, orally. All the patients received 5mg folic acid on all the 
days except the drug day.  
Successful genotyping of MTHFR A1298C was observed in 96 RA patients and 44 
control subjects. The frequency of MTHFR A1298C polymorphism was determined in RA 
patients and control subjects and presented in Table 2. The heterozygous polymorphism 
AC was found to be higher in control subjects (51%) and in RA patients (46.87%).  
After 3months follow-up period 42 RA patients completed the study. There were 
13 wild-type, 29 heterozygous genotypes and 10 homozygous genotypes. In order to study 
the relationship between MTX-related efficacy and toxicity, their disease characteristics, 
dose profile, biochemical parameters and adverse effect profiles were studied. (Table 3, 
Table 4, Table 5 and Table 6) 
The efficacy related parameters comprised of morning stiffness, pain scale, tender 
and swollen-joint counts, and disease activity score(DAS), health assessment 
questionnaire(HAQ) scoring and weekly dose of MTX were studied.  
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The relief in morning stiffness was found to be significantly improved among AC 
(p<0.001) and AA genotypes (p<0.05) Fig 1& 4. Even though the morning stiffness 
decreased among the CC genotypes, it was not statistically significant.  
There was a significant decrease in tender joint count in AA genotypes (p<0.05)   
Fig 2.  
There was no significant difference in pain scale among all the genotypes.  
Swollen joint count was significantly increased in CC genotypes when compared to 
AC genotypes (p<0.05) Fig 16.  
The DAS was significantly increased (p<0.01) in CC genotypes in final visit Fig 7.  
There was no significant difference among AA and AC genotypes between the 
visits.  
Disability index measured by health assessment questionnaire was compared in all 
the visits. AC and CC genotypes, showed statistically significance (p<0.001) when 
compared to AA   Fig 5, 8, 12, 13, 20 & 21.  
In the CC genotypes the dose of MTX required for remission increased 
significantly  when compared to AA and AC genotypes (p<0.05) Fig 17.  
Among biochemical profile, ESR was significantly elevated in the CC genotypes  
Fig 9.  
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Regarding adverse effects, elevation of transaminases was taken as a marker of 
liver toxicity and nausea, vomiting was considered as gastrointestinal (GI) side effects. 
Other adverse effects like alopecia, pulmonary fibrosis and bone marrow depression were 
looked for, but they were not detected or reported by the patients who had completed the 
follow-up phase of the study. (Table 3, Table 4, Table 5 and Table 6)  
When compared to the initial visit SGOT was significantly increased in the wild-
type (p<0.05) and AC genotypes (p<0.05) Fig 3 & 6. There was a marked elevation of 
SGOT and SGPT in the CC genotypes in the final visit (p<0.01) Fig 10 & 11.  
In comparison of adverse effect profile of AC and CC genotypes with wild-type, 
the elevation of transaminases was significantly higher in the AC &CC genotypes (p<0.05) 
Fig 18 & 19.  
The CC genotypes had significant increase in SGOT (p<0.001) and SGPT 
(p<0.001) in final visit, when compared to AA and AC genotypes in final visit Fig 23 & 
24.  
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Table 1- Demographic and Clinical characteristics of RA patients and controls 
 
 
 
 
 
 
 
 
 
 
 Table 2 – Frequency Distribution of MTHFR A1289C (AA, AC & CC) 
 
 
 
 
 
 
 
 
                                   
 RA patients  Controls  
Age ( in years) 43.53 ± 8.98 44.14 ± 10.19 
Gender (Female/Male) 75/25 32/18 
Duration of disease  (in years) 2 ± 0.69  
Duration of MTX treatment (in years) 1.38 ± 0.47  
Dose of MTX (mg/week) 9.25 ± 2.5  
 Control 
(N=43) 
Rheumatoid arthritis 
(N=96) 
AA (Wild-type) 14 (32.6%) 30 (31.3%) 
AC (Heterozygous Mutants) 22 (51.16%) 45 (46.87%) 
CC (Homozygous Mutants 7 (16.28%) 21 (21.88%) 
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Comparison of Initial and Final visits of Wild-type, Heterozygous 
Mutants & Homozygous Mutants (Figure 1 to 11 and the values from 
Table 3) 
Wild type (AA Genotype) 
     
Morning Stiffness - Wild type
Initial visit Final visit 
0
10
20
30
40
50
60
*
m
in
 
Figure 1: Comparison of morning stiffness of AA genotype during initial and final 
visit was 53.8 ± 14.7 and 46.5 ± 10.7 (*p<0.05) and considered statistically significant 
 
Tender Joint Count - Wild type
Initial visit Final visit 
0
1
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3
4
5
*
(0
-2
8
)
 
Figure 2: Comparison of tender joint count of AA genotype during initial and final 
visit was 4.5 ± 1.4 and 3.8 ± 1.2(*p<0.05) and considered statistically significant 
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SGOT - Wild type
Initial vist Final visit
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Figure 3: Comparison of tender joint count of AA genotype during initial and final 
visit levels were 18.5 ± 4.4 and 22.8 ± 5.4 (*p<0.05) and considered statistically 
significant 
 
 
Heterozygous Mutants (AC Genotype) 
 
Morning Stiffness- Heterozygous Mutants
Initial vist Final visit
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Figure 4: Comparison of morning stiffness of AC genotype during initial and final visit 
was 51.4 ± 14.0 and 38.3 ± 11.6 (***p<0.001) and considered statistically significant 
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Health Assessment Questionnaire - Heterozygous Mutants
Initial visit Final visit
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Figure 5: Comparison of Health Assessment Questionnaire of AC genotype during 
initial and final visit was 1.48 ± 0.14 and 2.01 ± 0.19 (***p<0.001) and considered 
statistically significant 
 
 
SGPT- Heterozygous Mutants
Initial visit Final visit 
0
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Figure 6: Comparison of SGPT of AC genotype during initial and final visit was 19.3 
± 6.7 and 27.4 ± 7.7 (*p<0.05) and considered statistically significant 
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Homozygous Mutants (CC Genotype) 
 
Disease Activity Score - Homozygous Mutants
Initial visit Final visit 
0
1
2
3
4
5 **
 
Figure 7: Comparison of DAS of CC genotype during initial and final visit was 4.01 ± 
0.4 and 4.6 ± 0.4 (**p<0.01) and considered statistically significant 
 
Health Assessment Questionnaire - Homozygous Mutants
Initial visit Final visit
0.0
0.5
1.0
1.5
2.0 ***
(0
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)
 
Figure 8: Comparison of HAQ of CC genotype during initial and final visit was 1.51 ± 
0.23 and 1.94 ± 0.16 (***p<0.001) and considered statistically significant 
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Erythrocyte Sedimentation Rate - Homozygous Mutants
Initial visit Final visit 
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Figure 9: Comparison of ESR of CC genotype during initial and final visit was 19 ± 
4.6 and 39.3 ± 13.8 (**p<0.01) and considered statistically significant 
 
 
SGOT- Homozygous Mutants
Initial visit Final visit 
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Figure 10: Comparison of SGOT of CC genotype during initial and final visit was 22.6 
± 11.0 and 64.88 ± 31 (**p<0.01) and considered statistically significant 
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SGPT- Homozygous Mutants
Initial visit Final visit 
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Figure 11: Comparison of SGPT of CC genotype during initial and final visit was 19.9 
± 5.1 and 72.13 ± 40.2 (**p<0.01) and considered statistically significant 
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Comparison of Initial and Final visits of Wild-type Vs Mutants 
(Heterozygous Mutants & Homozygous Mutants) (Figure 12 to 15 and 
the values from Table 4) 
Health Assessment Questionnaire - Homozygous Mutants-Initial
Wild type Mutants
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Figure 12: Comparison of HAQ of AA (Vs.) CC +AC genotype during initial visit was 
0.76 ± 0.13 and 1.5 ± 0.17 (***p<0.001) and considered statistically significant 
Health Assessment Questionnaire - Homozygous Mutants-Final visit
Wild type Mutants
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)
Figure 13: Comparison of HAQ of AA (Vs.) CC+ AC genotype during Final visit was 
0.70 ± 0.09 and 2.0 ± 0.18 (*p<0.001) and  considered statistically significant 
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SGOT- Final visit
Wild-type Mutants
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Figure 14: Comparison of SGPT of AA (Vs.) CC + AC genotype during Final visit 
was 22.8 ± 5.4 and 38.4 ± 33.7 (*p<0.05) and considered statistically significant 
 
 
SGOT- Final visit
Wild-type Mutants
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Figure 15: Comparison of SGOT of AA (Vs.) CC + AC genotype during Final visit 
was 21.7 ± 3.9 and 41.5 ± 40.9 (*p<0.05) was considered statistically significant 
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Comparison of Initial and Final visits of Heterozygous Mutants Vs 
Homozygous Mutants (Figure 16 to 19 and values from Table 5) 
Swollen Joint Count - Heterozygous vs Homozygous Mutants
Initial visit Final visit 
0
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)
 
Figure 16: Comparison of Swollen joint count of AC and CC genotype during Final 
visit was 1.7 ± 0.9 and 2.6 ± 0.8 (*p<0.05) and considered statistically significant 
 
Weekly dose of MTX - Heterozygous vs Homozygous Mutants
Heterozygous Homozygous
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Figure 17: Comparison of weekly dose of MTX of AC and CC genotype during final 
visit was 9.5 ± 2.0 and 12.0 ± 3.9 (*p<0.05) and considered statistically significant 
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SGOT - Heterozygous vs Homozygous Mutants
Heterozygous Homozygous
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Figure 18: Comparison of SGOT of AC and CC genotype during final visit was 27.3 ± 
8.4 and 64.9 ± 31.0 (***p<0.001) and considered statistically significant 
SGPT - Heterozygous vs Homozygous Mutants
Heterozygous Homozygous
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Figure 19: Comparison of SGPT of AC and CC genotype during final visit was 27.4 ± 
7.7 and 72.13 ± 40.2 (***p<0.001) and considered statistically significant 
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Comparison of Initial and Final visits of Wild Vs Homozygous 
Mutants Vs Heterozygous Mutants (Figures 20 to 24 and values from 
Table 6) 
Health Assessment Questionnaire - Wild vs Homozygous vs Heterozygous Mutants- Initial
Wild-type Heterozygous Homozygous
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)
Figure 20: Comparison of HAQ of AA, AC and CC genotype during initial visit was 
0.76 ± 0.13, 1.48 ± 0.14 and 1.51 ± 0.23 (***p<0.001) and considered statistically 
significant 
 
Health Assessment Questionnaire - Wild vs Homozygous vs Heterozygous Mutants- Final
Wild-type Heterozygous Homozygous
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Figure 21: Comparison of HAQ of AA, AC and CC genotype during final visit was 
0.70 ± 0.09, 2.01 ± 0.19 and 1.94 ± 0.16 (***p<0.001) and considered statistically 
significant 
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Weekly dose of MTX - Wild-type vs Heterozygous vs Homozygous Mutants
Wild-type Heterozygous Homozygous
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g
Figure 22: Comparison of Weekly dose of MTX of AA, AC and CC genotype during 
final visit was 9.6 ± 2.0, 9.5 ± 2.0 and 12.0 ± 3.9 (*p<0.05) and considered statistically 
significant 
 
 
SGOT- Wild-type vs Heterozygous vs Homozygous Mutants
Wild-type Heterozygous Homozygous
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Figure 23: Comparison of SGOT of AA, AC and CC genotype during final visit was 
22.8 ± 5.4, 27.3 ± 8.4 and 64.9 ± 31.0 (***p<0.001, ###p<0.001) and considered 
statistically significant 
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SGPT- Wild-type vs Heterozygous vs Homozygous Mutants
Wild-type Heterozygous Homozygous
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Figure 24: Comparison of SGOT of AA, AC and CC genotype during final visit was 
21.7 ± 3.9, 27.4 ± 7.7 and 72.13 ± 40.2 (***p<0.001, ###p<0.001) and considered 
statistically significant 
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PCR and RFLP Products of MTHFR A1298C gene 
 
Figure 25: UV-Trans-illuminated agarose gel photo of the MTHFR 1298 A>C genes 
PCR Product and samples resolved in 3% agarose gel using 1XTBE buffer in 135V for 
30mins 
    L      1           2 3               4              5              6             7             L 
 
Figure 25: UV-Trans-illuminated agarose gel photo of the MTHFR 1298 A>C genes 
PCR-RFLP Product using Mbo II enzyme and samples Dissolved in 3% agarose gel 
using 1XTBE buffer in 135V for 30mins. 
L- Ladder gene (50bp); 1- Wild type (AA Genotype); 2,3,5 and 7- Heterozygous 
Mutant (AC genotype); 4- Homozygous Mutant (CC genotype) 
128 bp 
100 bp 
72 bp 
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DISCUSSION 
Rheumatoid arthritis is an autoimmune disease that results in a chronic, Systemic 
inflammatory disorder that affects many tissues and organs, but principally affects the 
flexible (synovial) joints. It can be a disabling and painful condition, which can lead to 
substantial loss of functioning and mobility if not adequately treated. 
 Methotrexate is the cornerstone for the therapy of rheumatoid arthritis in spite of 
the advent of newer biologics. MTX is fast acting and has best efficacy: toxicity ratio and 
also cheaper. Due to the variation in response and toxicity profile, 1/3
rd
 of the patients 
discontinue therapy due to its adverse effects. 
At cellular level MTX and MTX-PGs (metabolite of MTX) inhibit several enzymes 
of purine, pyrimidine biosynthesis and also exert anti-inflammatory effect. MTHFR is one 
of such enzyme inhibited by MTX. So the study in the polymorphism of MTHFR gene can 
be a better tool to reveal the efficacy: toxicity of MTX. 
This study was done in the Department of Rheumatology at Rajiv Gandhi 
Government General Hospital, Madras Medical College, Chennai. A total of 100 patients 
were enrolled for this study and after 3months follow-up period 42 RA patients completed 
the study. Successful genotyping of MTHFR A1298C was observed in 96 RA patients and 
44 control subjects. The frequency of MTHFR A1298C polymorphism was determined in 
RA patients and control subjects.  
 During enrolment patients were assessed by clinical examination and lab 
investigations and they were repeated after 3 months. Data were compiled and results 
analysed statistically. 
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The efficacy related parameters comprised of morning stiffness, pain scale, tender 
and swollen-joint counts, and disease activity score, health assessment questionnaire 
scoring and weekly dose of MTX. Toxicity related parameters were SGOT, SGPT and GI 
symptoms. 
The most widely reported polymorphisms were C677T and A1298C, in MTHFR 
gene which is associated with efficacy and adverse effects. In 1998, MTHFR A1298C has 
been reported by Weisberg et al, which causes glutamine to alanine substitution and 
renders reduced activity of the enzyme. In A1298C polymorphism the homozygous 
mutants have about ~40% reduction in enzyme activity. 
In our study, the frequency distribution of genetic polymorphism in south Indian 
healthy subjects is 32.6% and 67.44% respectively for wild-type and mutants, which is 
contradictory to a study conducted at Pune, European and African population. In Pune 
study the frequency of this polymorphism was reported to be 70% and 30% for wild-type 
and mutants respectively, in a total of one hundred and forty four unrelated healthy 
subjects, which is similar to European population. In African healthy subjects, the 
frequency was reported to be 87% and 13% by Yogita et al.
 [59]
 The reason for this 
difference could be due to Ethnic variation. 
In our study the frequency distribution of polymorphism in RA patients were 
observed as 31.3 : 68.75 for A and C alleles respectively, which is contradictory to a study 
conducted  in Japanese RA patients by Sachie Inoue et al,
[55]
 the frequency of A:C were 
76:24 respectively. A study in Israel RA patients by Berkun et al,
[49]
 it was reported as 53.8 
: 46.2 for A and C alleles respectively. A study in Afro-Americans by Hughes et al.,
[53]
 it 
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was found to be 74 : 26 and in Caucasians it was reported as 45 : 55. This proves racial 
differences in the allelic frequency.  
Berkun et al,
[49]
 reported that the allele frequency of 1298CC was higher in RA 
population and the carriers of 1298AA allele had higher frequency of adverse effects in 
spite of higher folic acid supplementation and 1298CC may protect against MTX related 
adverse effects, conducted in 93 RA patients in Israel. In our study, similarly 1298CC was 
higher in RA population but the frequency of adverse effects was higher in the CC 
genotype and is not protective of MTX-related adverse effects. Instead, CC genotype is 
predictive of adverse effects in spite of folate supplementation. The reason for this 
difference could be due to Ethnic variation and probably be attributed to smaller sample 
size of the study. 
In our study 1298AA genotypes were associated with better response to MTX 
treatment and lower incidence of adverse effects, whereas the 1298C allele carriers are 
prone for adverse effects. In a study by Wessels et al,
[58]
 who reported that MTHFR 
1298AA was associated with less improvement relative to mutants, which is contradictory 
to our study and MTHFR 1298C allele carriers, developed more adverse effects. Whereas 
Graber et al reported that MTHFR A1298C polymorphism is protective related to adverse 
effects of MTX, which is a contradictory to above finding.  Polygenetic analysis will 
address this limitation. 
In our study, the elevation in transaminases and GI adverse events in spite of folate 
supplementation was found to be higher in 1298CC genotype than the 1298AC and this 
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polymorphism warrants susceptibility to MTX toxicity. This is similar to the results of the 
study conducted by Davis et al.
[52] 
In our study the proportion of patients experiencing toxicity is found to be higher in 
1298CC genotypes than 1298AA genotypes and this is similar to the study conducted by 
Choe et al,
[51]
 in Korean RA patients. 
In our study the 1298AA genotype shows better improvement comparable to 
1298CC genotypes. The DAS score and HAQ score increased insignificantly for 1298CC 
genotype and the dose required for remission has also increased and they could become 
non-responders if the drug is administered chronically. This is similar to the results of 
study conducted by Kato et al.
[54] 
Urano et al,
[56]
 in 2002 assessed both C677T & A1298C polymorphisms in this 
gene and found A1298C polymorphism rendered the patients sensitive to MTX treatment, 
whereas C677T rendered the patients prone for toxicity. In haplotype analysis 677C-1298C 
were receiving lower dose of MTX and 677T-1298A had a higher frequency of side-effects 
from MTX. The reported toxicities were elevation of transaminases, gastrointestinal (GI) 
disturbances, hair loss, fatigue and rash. The same was confirmed in their second study 
published in the year 2007. In their subsequent study in 2009, the same group also reported 
that these two polymorphisms are not associated with the occurrence of fracture. In our 
study, haplotype-analysis was not done and further studies are essential to study the 
interaction of these two polymorphisms in the MTHFR gene.  
Assessment of the genotypes could be useful to identify the subset of genotypes 
such as 1298CC and their relative phenotypes and appropriate dose decisions with track of 
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adverse effects could be useful to assess better clinical response. This study proves 
pharmacogenetics could be a tool for assessing the treatment outcomes. Larger sample 
size, haplotype analysis and investigation of other genes contributing to the enzymatic 
pathway of methotrexate could guide clinicians in tackling variations in clinical toxicity 
and efficacy in rheumatoid arthritis.  
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CONCLUSION 
The study concludes that 
 The frequency distribution of genetic polymorphism of MTHFR A1298C gene 
was different among control and RA patients.  The 1298CC genotype was 
higher in RA patients compared to control group. 
 The 1298AA genotype shows better efficacy and lower incidence of toxicity to 
MTX therapy in the RA patients. 
  The 1298CC genotype shows elevation in transaminases and GI adverse events 
in spite of folate supplementation to MTX therapy in the RA patients. 
 The RA patients with 1298AA genotype found were to be good responders and 
1298CC genotype patients show poor response to MTX therapy in RA.  
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PROFORMA 
Baseline visit (Visit 1) 
Visit Date             RCC.No: 
OP/IP No: 
Demographic data 
 
State:           District: 
Name:          DOB/AGE: 
Gender:    M  F               Marital Status: 
Weight:                  Kg      Height:                               cm 
Employment/Income: 
Smoker /Alcoholic        Family History of RA:  
Previous history of Jaundice:                      
 
MEDICAL HISTORY 
Duration of RA:                
 
Concomitant illness:  SHT/DM/CHD/Dyslipidimea/Obesity 
Others 
Concomitant treatment  Yes   No 
 
 
 
 
Details of concomitant treatment 
 
MTX dose (mg/week)  :  
Folic acid dose               : 
Any other drug              : CQS/SSZ/Prednisolone/NSAID 
 
LABORATORY ASSESSMENTS 
Clinical pathology      Biochemistry 
Hb    g/dl    RBS                                            (mg/dl) 
TC      (cells/cu.mm)   Urea                                               (mg/dl) 
DC N%       L%        M%  E%   Creatinine                            (mg/dl) 
ESR:    mm/Hr    T.B/D.B                                          (mg/dl) 
Platelets                                           (cells/cu.mm)  Total protein                              (g/dl) 
Peripheral smear      Albumin                                           (g/dl) 
Urine Albumin       SGOT                                                 (U/L) 
               Sugar       SGPT     (U/L) 
         Deposits       SAP    (U/L) 
Immunology 
RF    (IU/ml) 
CRP    (mg/L) 
 
ADVERSE DRUG REACTION 
GI disturbances (nausea, vomiting, stomatitis) 
Abnormalities 
Any others 
 CLINICAL EVALUATION 
Morning stiffness 
Duration of morning stiffness in minutes: 
Grip strength: 
Reading in mmHg 
 1 2 3 Average 
Right     
Left     
 
Pain Visual analogue scale              
 
 
Patient’s assessment: 
Doctor’s assessment: 
 
 
Genetic information (MTHFR A1298C) 
Allele :    AA (wild-life) 
    CA (Heterozygous mutant) 
    CC (Homozygous mutant) 
Comments: 
  
 
 
 
No Pain Slight Moderate Severe Excruciating 
     
     
  
 
 
Number of affected Joints: 
 
 
Patient Global Health: 
    
     0         100 
INFORMED CONSENT FORM 
 
 
Title of the study:  “ A study on the clinical profile and pharmacogenetics of methotrexate treatment  in  
          patients  with  rheumatoid arthritis ”. 
 
Name of the Participant   :  
Name of the Principal investigator :  J.Sivaraman 
Name of the Institution   : Madras Medical College,Chennai-03. 
 
I _____________________________ have read the information in the form (or it has been read to me). I 
was free to ask any questions and they have been answered. I am over 18 years of age and, exercising my 
free power of choice, hereby give my consent to be included as a participant in “ A study on the clinical 
profile and pharmacogenetics of methotrexate treatment  in patients with Rheumatoid arthritis ” 
 
1. I have read and understood this consent form and the information provided to me.  
 
2. I have had the consent document explained to me.  
 
3. I have been explained about the nature of the study.  
 
4. I have been explained about my rights and responsibilities by the investigator.  
 
5. I have been informed the investigator of all the treatments I am taking or have taken in the past  
 
6    months including any native (alternative) treatment.  
 
6. I have been advised about the risks associated with my participation in this study.  
 
7. I agree to cooperate with the investigator and I will inform him/her immediately if I suffer 
unusual symptoms.  
  
8. I have not participated in any research study within the past   6 month(s).  
 
9. I have not donated blood within the past 6 months 
10. I am aware of the fact that I can opt out of the study at any time without having to give any reason 
and this will not affect my future treatment in this hospital.  
 
11. I am also aware that the investigator may terminate my participation in the study at any time, for 
any reason, without my consent.  
 
12. I hereby give permission to the investigators to release the information obtained from me as a 
result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and 
IEC. I understand that they are publicly presented.  
 
13. I have understood that my identity will be kept confidential if  my data are publicly presented  
 
14. I have had my questions answered to my satisfaction.  
 
15. I have decided to be in the research study.  
 
I am aware that if I have any question during this study, I should contact the investigator. By signing 
this consent form I attest that the information given in this document has been clearly explained to me 
and understood by me, I will be given a copy of this consent document. 
 
 
 
  
Name and signature / thumb impression of the participant (or legal representative if participant 
 
incompetent) 
 
Name   _________________________ Signature_________________ Date________________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name   _________________________ Signature_________________ Date________________ 
 
Address and contact number of  the impartial witness: 
 
 
 
 
 
 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _________________________ Signature_________________ Date________________ 
.
Information  to  Participants 
 
 
 
  
Principle Investigator  :   J.Sivaraman 
Name of  Participant   : 
 
 
Title: “A STUDY ON THE CLINICAL PROFILE AND PHARMACOGENETICS OF 
METHOTREXATE TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS”   
 
You are invited to take part in this study. The information in this document is meant to help you 
decide whether or not to take part. Please feel free to ask if you have any queries or concerns. 
 
You are being asked to participate in this study being conducted in Madras Medical College 
 
and Government General Hospital. 
 
This study will be done on the patients with RHEUMATOID ARTHRITIS who are on a drug 
called Methotrexate therapy alone. If you are eligible to participate in this study, you will be 
enrolled. We will obtain some of your medical/treatment data from your records. You will have 
to provide 5ml Blood sample for pharmacogenetic testing 
 
 
We have obtained approval from the Institutional Ethics Committee, Madras Medical College. 
 
Pharmacogenetics means the study of genetic variability in drug response. So analysis of genes 
responsible for efficacy and toxicity can be analyzed in every individual who are participating in 
this study. This study data may gives you the optimized treatment. 
 
Improvement of your condition will be assessed by DAS and HAQ scoring and also by 
examining your blood sample for C-Reactive protein and Erythrocyte sedimentation rate. For 
this you may be required to provide 5ml of blood at 6 month interval for 1 year. 
 
If you notice any adverse effects to the treatment drug (MTX), you may report to us and it will 
be recorded. 5ml of blood will be collected at 3 months interval to assess the toxic effects of 
MTX on liver functions. So the total amount of blood will be collected through out of the study 
will be 30ml. 
 
This study involves only analysis of blood and collection of data. There will be no risk involved. 
You will not be charged for the analysis of blood samples. Pharmacogenetic analysis may 
provide benefits to the society in terms of advancements of medical knowledge and/or 
therapeutic benefits for management of RHEUMATOID ARTHRITIS 
 
You have the right to confidentiality regarding the privacy of your medical information (personal 
details, results of physical examinations, investigations, and your medical history). By signing 
this document, you will be allowing the research team investigators, other study personnel, 
sponsors, IEC and any person or agency required by law like the Drug Controller General of 
India to view your data, if required. 
 The information from this study, if published in scientific journals or presented at scientific 
meetings, will not reveal your identity. 
 
Your decisions to not participate in this research study will not affect your medical care or your 
relationship with investigator or the institution. Your doctor will still take care of you and you 
will not loose any benefits to which you are entitled. 
 
The participation in this research is purely voluntary and you have the right to withdrawal from 
this study at any time during course of the study without giving any reasons. 
 
. 
 
 
Name of the participant:     Name of the Investigator: 
 
Signature:       Signature:    
      
Date:        Date:
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LIST OF ABBREVIATIONS USED 
 
ABCB1 ATP-binding cassette proteins 
ADA Adenosine deaminase 
ADORA Adenosine receptors 
ADP Adenosine diphosphate 
AICAR 5-aminoimidazole- 4-carboxamide ribonucleotide 
AMP Adenosine monophosphate 
AMPD Adenosine monophosphate deaminase 
ATIC 
5-aminoimidazole- 4-carboxamide ribonucleotide 
transformylase 
ATP Adenosine triphosphate 
bp Base pair 
CAD Coronary artery diseases 
CQS Chloroquine 
CRP C-Reactive protein 
dATP   Deoxy adenine triphosphate 
DC Differential count 
dCTP  Deoxy cytosine triphosphate 
dGTP  Deoxy guanine triphosphate  
DHF Dihydrofolate 
DHFR Dihydrofolate reductase 
DM Diabetes mellitus 
DNA Deoxy-ribo Nucleic Acid 
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dNTp Deoxy nucleotide tri phosphate 
dTMP Deoxy thymidine monophosphate 
dUMP Deoxy uridine monophosphate 
EDTA Ethylene Diamine Tetra acetic acid 
ESR Erythrocytes sedimentation rate 
FAICAR 10, formyl AICAR 
FP Forward primer 
FPGS Folylpolyglutamate synthase 
GGH Gamma-glutamyl hydrolase 
H Healthy individuals 
HB Haemoglobin 
IEC Institutional ethics committee  
IMP Inosine monophosphate 
ITP Inosine triphosphate 
ITPA Inosine triphosphate pyrophosphatase 
IU International Units 
MS Methionine synthase 
MTHFR Methylenetetrahydrofolate reductase 
MTRR Methionine synthase reductase 
MTX Methotrexate 
MTX-PGs Polyglutamated MTX 
NSAID Non-steroidal anti-inflammatory drugs 
PCR Polymerase chain reaction 
RA Rheumatoid arthritis 
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RBC Red Blood Cells 
RBS Random blood sugar 
RF Rheumatoid factor 
RFC Reduced folate carrier 
RFLP Restriction fragment length polymorphism 
RNA Ribo Nucleic Acid 
RP Reverse primer 
RPM Revolutions per minute 
SDS Sodium dodecyl sulphate 
SGOT Serum glutamate oxaloacetic transaminase 
SGPT Serum glutamic pyruvic transaminase 
SHMT Serine hydroxyl methyl transferase 
SJC Swollen joint count 
SNP Single nucleotide polymorphisms 
SSZ Sulfasalazine 
TC Total count 
THF Tetrahydrofolate 
TJC Tender Joint count 
TYMS or TSER Thymidylate synthase 
WBC White Blood Cells 
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LIST OF CLINICAL PARAMETERS USED 
DISEASE CHARACTERISTICS 
 Morning stiffness (in Minutes) 
o Expressed in minutes. 
 Pain scale(0-10) 
o 0 indicates no pain and the value 10 indicates Extreme pain. 
 TJC (0-28) 
o Tender joint count ranges from 0 to 28. 
 SJC (0-20) 
o Swollen joint count ranges from 0 to 28 
 DAS ( calculated by using three variables TJC, SJC and ESR)  
o DAS score can be calculated by using the following formula 
DAS = 0.56* sqrt (TJC28) + 0.28* sqrt (SJC28) + 0.70* In(ESR)  
 HAQ(0-3) 
o Health Assessment Questionnaire values are between 0-3. The value 0 
indicates activity of daily living without any difficulty and the value 3 
indicates extreme difficulty in daily activities 
 
DRUG CHARACTERISTICS 
 Dose of MTX 
o Dose of methotrexate expressed as mg/week. 
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BIOCHEMICAL CHARACTERISTICS 
 ESR 
o Expressed as mm/Hr. ( Male: 0- 15mm/Hr., Female: 0-20mm/Hr.) 
 SGOT 
o Expressed as U/L ( Normal value 5 to 40 U/ L) 
 SGPT 
o Expressed as U/L ( Normal value 7 to 56 U/L) 
 
GI SYMPTOMS 
 This includes Nausea and Vomiting. 
